SEARCH

SEARCH BY CITATION

In the March/April 2002 issue, in the article titled “ Cancer Anorexia-Cachexia Syndrome: Current Issues in Research and Management” (Inui A. CA Cancer J Clin 2002;52:72–91), the author inadvertently omitted citing reference 88 for the article titled “ Cancer Cachexia: A Therapeutic Approach” (Argilés JM, Meijsing SH, Pallarés-Trujillo J, et al. Med Res Rev 2001;21:83–101) in the following two sentences:

On page 83, the sentence reads as follows: “Future clinical trials with other antiserotonergic drugs are needed to define the role of the serotonergic system in the development of cancer cachexia.”

On page 84, the sentence reads as follows: “5′-dFUrd is a cytostatic agent that is converted on metabolization into the active 5-fluororacil (5-FUra) by pyrimidine (thymidine and uridine) phosphorylases, which are very active in tumor tissue.”

In addition to omitting reference 88, the sentence has been revised to read as follows: “5′deoxy-5-fluorouridine (5′-dFUrd) is a cytostatic agent that is converted upon metabolization on the active metabolite Fluorouracil (5-FUra) by uridine and thymidine phosphorylases, which are very active in tumor.”

The authors regret these errors and apologize for any confusion this may have caused.